<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03709992</url>
  </required_header>
  <id_info>
    <org_study_id>Trospium vs Tamsulosin</org_study_id>
    <nct_id>NCT03709992</nct_id>
  </id_info>
  <brief_title>Trospium Chloride vs Tamsulosin in Treatment of Ureteral Stent Related Symptoms:</brief_title>
  <official_title>Trospium Chloride vs Tamsulosin in Treatment of Ureteral Stent Related Symptoms: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amiri Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted to compare the efficacy and safety of Trospium chloride versus
      Tamsulosin for treatment of ureteral stent related symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients will be randomized to one of the two treatment groups. Group 1 patients
      will receive 30 mg of Trospium chloride tablet twice daily, while group 2 patients will
      receive 0.4 mg of Tamsulosin tablet once daily, until the stent is removed. Ureteral Stent
      Symptoms Questionnaire (USSQ) will be used to evaluate the symptoms of the patients with DJ
      stent after 2 weeks of inserting the stent.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Because of COVID-19 Crisis
  </why_stopped>
  <start_date type="Actual">February 18, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ureteral Stent Symptoms Questionnaire (USSQ) score</measure>
    <time_frame>14 days</time_frame>
    <description>Quantitative assessment of quality of life score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>14 days</time_frame>
    <description>Assessment of side effects of the drug used</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Ureter Stone</condition>
  <condition>Quality of Life</condition>
  <condition>Ureter Obstruction</condition>
  <arm_group>
    <arm_group_label>Trospium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive 30 mg of Trospium chloride tablet twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tamsulosin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive 0.4 mg of Tamsulosin tablet once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trospium Chloride</intervention_name>
    <description>30 mg of Trospium chloride tablet twice daily</description>
    <arm_group_label>Trospium</arm_group_label>
    <other_name>Spasmix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamsulosin</intervention_name>
    <description>0.4 mg of Tamsulosin tablet once daily</description>
    <arm_group_label>Tamsulosin</arm_group_label>
    <other_name>Omnic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with double &quot;J&quot; (DJ) stent after ureteroscopy or for drainage of obstructed
             kidney

        Exclusion Criteria:

          1. Patients with hypersensitivity to either Trospium chloride or Tamsulosin

          2. Patients with complications after DJ insertion (such as fever, hematuria, perforation,
             stent migration).

          3. Patients receiving alpha blockers or anticholinergic medications for any other reason.

          4. Patients with history of orthostatic hypotension.

          5. Pregnant or breastfeeding females.

          6. Patients with hepatic impairment (Child-Pugh score &gt;9).

          7. Patients with severe renal impairment with creatinine clearance of less than 15
             mL/min.

          8. Patients with narrow-angle glaucoma.

          9. Patients with history of urinary retention or gastric retention.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abdullatif AL-Terki, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Amiri Hospital - Kuwait</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Al-Amiri Hospital</name>
      <address>
        <city>Kuwait</city>
        <country>Kuwait</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kuwait</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 15, 2018</study_first_submitted>
  <study_first_submitted_qc>October 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2018</study_first_posted>
  <last_update_submitted>April 15, 2020</last_update_submitted>
  <last_update_submitted_qc>April 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>Ahmed R. EL-Nahas</investigator_full_name>
    <investigator_title>Professor of Urology</investigator_title>
  </responsible_party>
  <keyword>ureteral stent</keyword>
  <keyword>USSQ</keyword>
  <keyword>Tamsulosin</keyword>
  <keyword>Trospium Chloride</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ureteral Obstruction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
    <mesh_term>Trospium chloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

